Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New drug MTX-101 enters first human safety trials for type 1 diabetes

NCT ID NCT06324604

First seen Mar 28, 2026 · Last updated Apr 28, 2026 · Updated 6 times

Summary

This early-stage study tests a new drug called MTX-101 in healthy adults and people with type 1 diabetes. The main goal is to check for side effects and see how the drug moves through the body. Researchers will also look at how MTX-101 affects immune cells. The study involves up to 96 participants aged 18 to 65.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Austin Health

    RECRUITING

    Heidelberg, Victoria, 3084, Australia

    Contact

  • St Vincent's Hospital Melbourne (SVHM)

    RECRUITING

    Melbourne, Victoria, Austria

    Contact

  • The Royal Melbourne Hospital

    RECRUITING

    Melbourne, Victoria, 3050, Australia

    Contact

  • Wesley Research Institute

    ACTIVE_NOT_RECRUITING

    Auchenflower, Queensland, 4066, Australia

Conditions

Explore the condition pages connected to this study.